Abstract:The successful treatment of Cushing syndrome depends on specific therapy directed against the etiology of hypercortisolism. In addition to surgical procedures, various drugs have been employed in the management of this difficult disease. Compounds with neuromodulatory properties have been effective in only a limited number of cases of hypothalamic-pituitary-dependent Cushing disease, the most common form of Cushing syndrome. These agents include serotonin antagonists (cyproheptadine, ketanserin, ritanserin), dopamine agonists (bromocriptine, cabergoline), GABA agonists (valproic acid [sodium valproate]), and somatostatin analogs (octreotide). Interesting new avenues at the pituitary level involve the potential use of thiazolidinedione compounds, such as rosiglitazone, and of retinoic acid, which are ligands of different nuclear hormone receptors involved in hypothalamic-pituitary regulation. The most exciting news, however, in the pharmacologic approach to Cushing syndrome refers to the adrenal corticotropin (adrenocorticotropic hormone; ACTH)-independent forms, in which aberrant adrenal receptors, through the binding of their respective ligands, could lead to chronic cortisol overproduction. They include receptors for gastric inhibitory peptide (GIP), beta-adrenergic agonists, luteinizing hormone (LH)/human chorionic gonadotropin, serotonin (5-HT(4) receptor), vasopressin (V(1) receptor), and angiotensin II (AT(1) receptor). In GIP-dependent Cushing syndrome, the most frequent subtype of ACTH-independent macronodular adrenal hyperplasia associated with the presence of aberrant adrenocortical hormone receptors described so far, octreotide administration before each meal showed clinical efficacy only in the first few months, probably because of somatostatin receptor downregulation in GIP-secreting cells. Long-term medical treatments with propranolol and the gonadotropin-releasing hormone analog leuprorelin (leuprolide acetate) were effective in patients with catecholamine-dependent and LH-dependent Cushing syndrome, respectively. The oral vasopressin V(1) receptor antagonist OPC-21268 and the angiotensin II (AT(1)) receptor antagonist candesartan cilexetil were also able to decrease cortisol levels during the few days of administration of the drugs in patients with specific receptor abnormalities. These adrenal forms of Cushing syndrome are rare, and clinical data are scarce. Moreover, the real clinical significance of aberrant hormone receptors is still under investigation, as is the possibility of avoiding surgery by pharmacologic manipulation. Patients in whom these intriguing syndromes are suspected require detailed investigation protocols, which should be carried out in specialized centers. While awaiting further developments, the use of traditional medical treatment at the adrenal level with adrenal steroid inhibitors is still valuable in several instances.

High-throughput screening for Cushing disease: therapeutic potential of thiostrepton via cell cycle regulation

High-throughput screening for Cushing’s disease: therapeutic potential of thiostrepton via cell cycle regulation

Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone Production and Tumorous Corticotroph Cell Growth in AtT20 Cells

Recurrent Gain-Of-Function Usp8 Mutations in Cushing'S Disease

Screening of Various Immunopotentiators in Spontaneously Hypertensive Rats with T-Cell Depression

Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's Disease

Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing’s Disease

Effects Of Rxr Agonists On Cell Proliferation/Apoptosis And Acth Secretion/Pomc Expression

Drug development and potential targets for Cushing's syndrome

Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor

Regulation Of The Egfr Pathway By Hsp90 Is Involved In The Pathogenesis Of Cushing'S Disease

Pharmacologic management of Cushing syndrome : new targets for therapy

Treatment of Cushing Disease With Pituitary-Targeting Seliciclib

LBODP077 The Therapeutic Potential Of Targeting Histone Deacetylase For Pituitary Neuroendocrine Tumors By High-throughout Drug Screening

Autophagy inhibition suppresses hormone production and cell growth in pituitary tumor cells: A potential approach to pituitary tumors

Metformin inhibits cell proliferation and ACTH secretion in AtT20 cells via regulating the MAPK pathway

A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas

Ursolic Acid Suppresses Growth and Adrenocorticotrophic Hormone Secretion in AtT20 Cells As a Potential Agent Targeting Adrenocorticotrophic Hormone-Producing Pituitary Adenoma

USP8: a novel therapeutic target for Cushing’s disease

Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors

Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.